@article{9d8233c1dd7c44328364b1cd3aebdef2,
title = "The global landscape of tuberculosis therapeutics",
abstract = "Tuberculosis (TB) is one of the oldest infections afflicting humans yet remains the number one infectious disease killer worldwide. Despite decades of experience treating this disease, TB regimens require months of multidrug therapy, even for latent infections. There have been important recent advances in treatment options across the spectrum of TB, from latent infection to extensively drug-resistant (XDR) TB disease. In addition, new, potent drugs are emerging out of the development pipeline and are being tested in novel regimens in multiple currently enrolling trials. Shorter, safer regimens for many forms of TB are now available or are in our near-term vision. We review recent advances in TB therapeutics and provide an overview of the upcoming clinical trials landscape that will help define the future of worldwide TB treatment.",
keywords = "dose optimization, drug resistance, latent tuberculosis infection, tuberculosis",
author = "Tornheim, {Jeffrey A.} and Dooley, {Kelly E.}",
note = "Funding Information: K.E.D. is an investigator on trials sponsored by the National Institutes of Health, Centers for Disease Control and Prevention, US Food and Drug Administration, or Unitaid involving tuberculosis drugs, to include high-dose isoniazid, rifapentine, delamanid, pretomanid, bedaquiline, high-dose rifampicin, levofloxacin, meropenem, and amoxicillin-clavulanate, but receives no salary support or other funding from drug companies for these projects. Funding Information: J.A.T. was supported by several National Institutes of Health (NIH) organizations, including the Office of the Director of the Fogarty International Center; Office of AIDS Research; National Cancer Center; National Heart, Blood, and Lung Institute; and Office of Research for Women{\textquoteright}s Health through the Fogarty Global Health Fellows Program Consortium comprising the University of North Carolina, Johns Hopkins University, Morehouse College, and Tulane University (grant number R25TW009340), NIH National Institute of Allergy and Infectious Diseases (grant number K23AI135102), and the Johns Hopkins University Clinician Scientist Career Development Award. K.E.D. is supported by NIH grants R01AI111992 and R01HD074944 and US Food and Drug Administration grants R01FD004794 and R01FD-R-5724. Publisher Copyright: {\textcopyright} 2019 by Annual Reviews.",
year = "2019",
month = jan,
day = "27",
doi = "10.1146/annurev-med-040717-051150",
language = "English (US)",
volume = "70",
pages = "105--120",
journal = "Annual Review of Medicine",
issn = "0066-4219",
publisher = "Annual Reviews Inc.",
}